Status:
COMPLETED
Maintenance Therapy Using Lenalidomide in Myeloma
Lead Sponsor:
University Hospital, Toulouse
Collaborating Sponsors:
Intergroupe Francophone du Myelome
Celgene
Conditions:
Myeloma
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Maintenance treatment of myeloma.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- No signs of progression after transplant
- Effective contraception if necessary (oral contraception for females and barrier methods of contraception for sexually active males)
- No active severe infection
- Satisfactory restoration of the haematological parameters defined by: PN \>1,000/mm3 and Platelets \> 75,000/mm3
- Bilirubin \< 35 umol/l and GOT/GPT/PAL\<3N
- Creatinine \< 160 umol/l.
Exclusion
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2018
Estimated Enrollment :
614 Patients enrolled
Trial Details
Trial ID
NCT00430365
Start Date
June 1 2006
End Date
September 1 2018
Last Update
April 26 2019
Active Locations (77)
Enter a location and click search to find clinical trials sorted by distance.
1
ZNA Middelheim
Antwerp, Belgium, 2020
2
Algemeen Centrumziekenhuis Antwerpen
Antwerp, Belgium, 2060
3
UZA Antwerpen
Antwerp, Belgium, 2650
4
Hôpital Saint Joseph
Arlon, Belgium, 6700